newsfilter
← Latest News
Business Wire·

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel